Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1093/oxfordjournals.humrep.a019224 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Osimertinib as a neoadjuvant therapy in resectable EGFR-mutant non-small cell lung cancer: a real-world, multicenter retrospective study.
Transl Lung Cancer Res
December 2024
Department of Thoracic Surgery, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, Affiliated Cancer Hospital of University of Electronic Science and Technology of China (UESTC), Chengdu, China.
Background: Osimertinib, a third-generation tyrosine kinase inhibitor (TKI), has been authorized for use in patients with epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC). This study aimed to evaluate the effectiveness and safety of neoadjuvant osimertinib in individuals with resectable locally advanced NSCLC harboring EGFR mutation.
Methods: Ten centers located in mainland China took part in a single-arm, real-world, multicenter retrospective study (registration number: ChiCTR2100049954).
Systematic development and bioprinting of novel nanostructured multi-material bioinks for bone tissue engineering.
Biofabrication
January 2025
Department of Clinical Dentistry, Faculty of Medicine, University of Bergen, Årstadveien 19, Center of Translational Oral Research (TOR), Bergen, Bergen, 5020, NORWAY.
A functional bioink with potential in bone tissue engineering must be subjected to critical investigation throughout its intended lifespan. The aim of this study was to develop alginate-gelatin-based (Alg-Gel) multicomponent bioinks systematically and to assess the short- and long-term exposure responses of human bone marrow stromal cells (hBMSCs) printed within these bioinks with and without crosslinking. The first generation of bioinks was established by incorporating a range of cellulose nanofibrils (CNFs), to evaluate their effect on viscosity, printability and cell viability.
View Article and Find Full Text PDFFrom automated Raman to cost-effective nanoparticle-on-film (NPoF) SERS spectroscopy: A combined approach for assessing micro- and nanoplastics released into the oral cavity from chewing gum.
J Hazard Mater
December 2024
Institute for Global Food Security, School of Biological Sciences, Queen's University Belfast, Belfast, United Kingdom; Material and Advanced Technologies for Healthcare, Queen's University of Belfast, 18-30 Malone Road, Belfast BT9 5DL, United Kingdom. Electronic address:
Microplastics (MPs) and Nanoplastics (NPs), a burgeoning health hazard, often go unnoticed due to suboptimal analytical tools, making their way inside our bodies through various means. Surface Enhanced Raman Spectroscopy (SERS), although is utilized in detecting NPs, challenges arise at low concentrations due to their low Raman cross section and inability to situate within hotspots owing to their ubiquitous size and shape. This study presents an innovative and cost-effective approach employing household metallic foils (aluminium and copper) as nanoparticle-on-film (NPoF) substrates for targeting such analytes.
View Article and Find Full Text PDFSaliva microbiome profiling by full-gene 16S rRNA Oxford Nanopore Technology versus Illumina MiSeq sequencing.
NPJ Biofilms Microbiomes
December 2024
Department of Odontology, Umeå University, Umeå, Sweden.
Molecular characterization of the oral microbiome is a crucial first step in experiments which aim to understand the complex dynamics of the oral microbiome or the interplay with host health and disease. Third-generation Oxford Nanopore Technology (ONT) offers advanced long-read sequencing capabilities, which hold promise for improved molecular characterization by distinguishing closely related microbial species within oral ecosystems in health and disease states. However, the performance of ONT sequencing of oral samples requires validation, and the consistency of this approach across different analytical and sampling conditions is not well understood.
View Article and Find Full Text PDFEffect of furmonertinib on the pharmacokinetics of rivaroxaban or apixaban in vivo.
J Chromatogr B Analyt Technol Biomed Life Sci
January 2025
Department of Pharmacy, Hebei General Hospital, Shijiazhuang, China; Hebei Key Laboratory of Clinical Pharmacy, Shijiazhuang, China. Electronic address:
Article Synopsis
- Furmonertinib is a third generation EGFR-TKI used to treat non-small cell lung cancer (NSCLC), which often coexists with venous thromboembolism (VTE) that is treated using direct oral anticoagulants (DOACs) like rivaroxaban and apixaban.
- This study investigated how furmonertinib affects the pharmacokinetics of these DOACs in rats, revealing that it significantly increases the concentration and overall exposure (C and AUC) of both rivaroxaban and apixaban while decreasing their clearance (CL/F) and volume of distribution (V/F).
- The findings highlight the importance of recognizing furmonertinib’s impact on
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!